---
title: "BSX  Earnings: Boston Scientific Stock (BSX) Plunges 17% on Weak Guidance"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274836890.md"
description: "Boston Scientific (BSX) shares fell 17% following disappointing forward guidance despite reporting strong fourth-quarter 2025 results, with EPS of $0.80 and revenue of $5.29 billion. The company anticipates 8.5% to 10% revenue growth and earnings of $0.78 to $0.80 for Q1, below analyst expectations. For 2026, BSX forecasts earnings of $3.43 to $3.49 per share and revenue growth of 10% to 11%, aligning with consensus estimates. Additionally, BSX is acquiring Penumbra for $14.5 billion."
datetime: "2026-02-04T15:14:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274836890.md)
  - [en](https://longbridge.com/en/news/274836890.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274836890.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274836890.md) | [English](https://longbridge.com/en/news/274836890.md)


# BSX  Earnings: Boston Scientific Stock (BSX) Plunges 17% on Weak Guidance

Shares of Boston Scientific (BSX) are down 17% after the medical-device maker issued forward guidance that disappointed Wall Street.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

The company issued fourth-quarter 2025 financial results that beat Wall Street estimates. Boston Scientific, which makes pacemakers and stents used to treat heart conditions, reported earnings per share (EPS) of $0.80, above analysts' consensus forecast of $0.78.

Revenue in the final months of last year totaled $5.29 billion, up 12.7% from a year earlier and ahead of the $5.28 billion forecast on Wall Street. Despite the decent print, BSX stock is plunging after the company delivered an outlook that fell short of expectations.

## **Boston Scientific's Disappointing Guidance**

Looking ahead, Boston Scientific said that it expects 8.5% to 10% revenue growth and earnings of $0.78 to $0.80 for the current first quarter. Analysts had been looking for 9.8% sales growth and a profit of $0.80 a share from the company.

For all of 2026, Boston Scientific forecast per-share earnings of $3.43 to $3.49 and revenue growth of 10% to 11%. The full-year outlook is in line with analysts' consensus estimates. Boston Scientific recently announced that it is acquiring Penumbra (PEN), a maker of cardiovascular devices, for $14.5 billion.

## **Is BSX Stock a Buy?**

### 相關股票

- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Penumbra (PEN.US)](https://longbridge.com/zh-HK/quote/PEN.US.md)
- [Boston Scientific (BSX.US)](https://longbridge.com/zh-HK/quote/BSX.US.md)
- [iShares US Medical Devices (IHI.US)](https://longbridge.com/zh-HK/quote/IHI.US.md)
- [SPDR S&P Health Equip (XHE.US)](https://longbridge.com/zh-HK/quote/XHE.US.md)

## 相關資訊與研究

- [Boston Scientific (BSX) Gets a Hold from Erste Group](https://longbridge.com/zh-HK/news/281570952.md)
- [Boston Scientific receives FDA clearance for the Asurys™ Fluid Management System | BSX Stock News](https://longbridge.com/zh-HK/news/281002542.md)
- [Needham & Company LLC Reaffirms Buy Rating for Boston Scientific (NYSE:BSX)](https://longbridge.com/zh-HK/news/281016414.md)
- [Key facts: Boston Scientific CHAMPION‑AF and HI‑PEITHO Met Endpoints](https://longbridge.com/zh-HK/news/280887013.md)
- [15:24 ETBoston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit](https://longbridge.com/zh-HK/news/281658419.md)